Can steroids help cancer patients resume a promising therapy?
NCT ID NCT03847649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B allows patients from previous studies to continue receiving durvalumab, with or without another drug called tremelimumab. The goal is to see if this approach is safe and can help control cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (with prednisone or tremelimumab)
What this could lead to
If successful, this could offer a way for cancer patients who had severe side effects from immunotherapy to safely resume treatment and potentially control their disease.
What could go wrong
This is a small, early-phase study, so results may not apply broadly. There is a risk that side effects return or that the cancer does not respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BCCA - Kelowna
RECRUITINGKelowna, British Columbia, V1Y 5L3, Canada
Contact Phone: •••-•••-••••
-
BCCA - Vancouver
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-••••
-
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
Contact Phone: •••-•••-••••
-
CHUM-Centre Hospitalier de l'Universite de Montreal
RECRUITINGMontreal, Quebec, H2X 3E4, Canada
Contact Phone: •••-•••-••••
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
Contact Phone: •••-•••-••••
-
Juravinski Cancer Centre at Hamilton Health Sciences
RECRUITINGHamilton, Ontario, L8V 5C2, Canada
Contact Phone: •••-•••-••••
-
Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Contact Phone: •••-•••-••••
-
Regional Health Authority B, Zone 2
RECRUITINGSaint John, New Brunswick, E2L 4L2, Canada
Contact Phone: •••-•••-••••
-
Saskatoon Cancer Centre
RECRUITINGSaskatoon, Saskatchewan, S7N 4H4, Canada
Contact Phone: •••-•••-••••
-
University Health Network
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
Waterloo Regional Health Network (WRHN)
RECRUITINGKitchener, Ontario, N2G 1G3, Canada
Contact Phone: •••-•••-••••
-
Windsor Regional Cancer Centre
RECRUITINGWindsor, Ontario, N8W 2X3, Canada
Contact Phone: •••-•••-••••